Statement re: Media Speculation

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. For immediate release 11 July 2014 Shire plc Statement re: Media Speculation Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG) notes theBloomberg article this afternoon. Shire confirms it has held a meeting withrepresentatives of AbbVie. This statement is being made by Shire without the prior agreement or approvalof AbbVie. A further update will be made when appropriate. Shareholders are stronglyadvised to take no action in relation to AbbVie's proposal. There can be nocertainty that any firm offer will be made nor as to the terms on which anyfirm offer might be made. CONTACTS Shire Stephanie Fagan +1 201 572 9581 FTI Consulting (Media Adviser to theCompany) Andrew Lorenz (London) +44 77 7564 1807 Ben Atwell (London) +44 20 3727 1000 David B. Roady (New York) +1 212 850 5600 Robert Stanislaro (New York) +1 212 850 5600 A copy of this announcement will be available at www.shire.com. The content ofthe website referred to in this announcement is not incorporated into and doesnot form part of this announcement. NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We focus on providing treatments in Neuroscience, Rare Diseases,Gastrointestinal, and Internal Medicine and we are developing treatments forsymptomatic conditions treated by specialist physicians in other targetedtherapeutic areas, such as Ophthalmology. www.shire.com Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release www.shire.com